With growing demand for RWE in oncology for drug development and discovery and treatment, Atropos Health is adding oncology specific RWD, product features and experienced personnel to enhance experiences for clinicians and researchers
Atropos Health announces the expansion of its oncology solutions with new personnel and product features to meet the growing demand for real-world evidence (RWE) in cancer care. Cory D. Wiegert joins as Chief Operating Officer, Dr. Morgan Cheatham joins the Board of Directors as Board Observer, and Jason Jones joins to lead Data Science, all bringing invaluable experience across healthcare IT, AI, and data science. The company is also enhancing the Atropos Evidence™ Network with additional real-world data (RWD) sources, including Ontada and Norstella, to strengthen its federated Oncology MultiModal Network.